| Basics |
| Company: |
Y-mAbs Therapeutics, Inc. |
| IPO Date: |
September 17, 2018 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$256.19M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.62 | 3.24%
|
| Avg Daily Range (30 D): |
$0.18 | 2.79%
|
| Avg Daily Range (90 D): |
$0.29 | 2.93%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.25M |
| Avg Daily Volume (30 D): |
.44M |
| Avg Daily Volume (90 D): |
.3M |
| Trade Size |
| Avg Trade Size (Sh.): |
78 |
| Avg Trade Size (Sh.) (30 D): |
75 |
| Avg Trade Size (Sh.) (90 D): |
66 |
| Institutional Trades |
| Total Inst.Trades: |
1,097 |
| Avg Inst. Trade: |
$1.39M |
| Avg Inst. Trade (30 D): |
$1.38M |
| Avg Inst. Trade (90 D): |
$1.14M |
| Avg Inst. Trade Volume: |
.06M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.44M |
| Avg Closing Trade (30 D): |
$3.6M |
| Avg Closing Trade (90 D): |
$1.01M |
| Avg Closing Volume: |
63.69K |
|
|
|
|
| News |
Jul 1, 2024 @ 8:05 PM
Y-mAbs Appoints Seasoned Biopharma Executive Peter...
Source: Y-mAbs Therapeutics, Inc.
|
Jun 7, 2024 @ 11:05 AM
Y-mAbs Announces Preclinical GD2-SADA Data to be P...
Source: Y-mAbs Therapeutics, Inc.
|
Jun 5, 2024 @ 11:05 AM
Y-mAbs Deepens Radiopharmaceutical Leadership with...
Source: Y-mAbs Therapeutics, Inc.
|
Jun 1, 2024 @ 12:15 PM
Y-mAbs Announces Publication of Preclinical GD2-SA...
Source: Y-mAbs Therapeutics, Inc.
|
Jun 1, 2024 @ 12:05 PM
Y-mAbs Announces New Interim Analysis of Phase 2 D...
Source: Y-mAbs Therapeutics, Inc.
|
| Financials |
| |
TTM |
Q3 2024 |
Q2 2024 |
|
Basic EPS
|
$-.54
|
$-.16
|
$-.21
|
|
Diluted EPS
|
$-.54
|
$-.16
|
$-.21
|
|
Revenue
|
$ 84.55M
|
$ 18.46M
|
$ 22.8M
|
|
Gross Profit
|
$ 75.16M
|
$ 16.21M
|
$ 19.78M
|
|
Net Income / Loss
|
$ -23.86M
|
$ -7M
|
$ -9.25M
|
|
Operating Income / Loss
|
$ -28.46M
|
$ -8.57M
|
$ -9.79M
|
|
Cost of Revenue
|
$ 9.4M
|
$ 2.25M
|
$ 3.01M
|
|
Net Cash Flow
|
$ 19.2M
|
$ M
|
$ M
|
|
PE Ratio
|
|
|
|
|
